Concepedia

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

Natalia Sergina, Megan Rausch, Donghui Wang, Jimmy A. Blair, Byron Hann, Kevan M. Shokat, Mark M. Moasser

Nature · 2007 · 989 citations · 28 references

DOIFull text

Open access

Concepts

References

28

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/<i>neu</i>Oncogene

Dennis J. Slamon, Gary M. Clark, Steven Wong et al. · Science · 1987 · 11.7K citations

, , +14

Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia

Hagop Kantarjian, Charles L. Sawyers, Andreas Hochhaus et al. · New England Journal of Medicine · 2002 · 2K citations · Full text

, , +14

Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene

William J. Muller, Eric Sinn, Paul K. Pattengale et al. · Cell · 1988 · 1.2K citations

, , +14

Reversible Oxidation and Inactivation of Protein Tyrosine Phosphatases In Vivo

Tzu‐Ching Meng, Toshiyuki Fukada, Nicholas K. Tonks · Molecular Cell · 2002 · 1K citations · Full text

, , +13

Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.

Stacy L. Moulder, F. Michael Yakes, Senthil K. Muthuswamy et al. · PubMed · 2001 · 549 citations

, , +16